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Abstract
The inadvertent transmission of long incubating, untreatable and fatal neurodegenerative prionopathies, notably iatrogenic 
Creutzfeldt–Jakob disease, following transplantation of cadaver-derived corneas, pituitary growth, hormones and dura mater, 
constitutes a historical precedent which has underpinned the application of precautionary principles to modern day advanced 
cell therapies. To date these have been reflected by geographic or medical history risk-based deferral of tissue donors. Emer-
gent understanding of other prion-like proteinopathies, their potential independence from prions as a transmissible agent 
and the variable capability of scalably manufacturable stem cells and derivatives to take up and clear or to propagate prions, 
substantiate further commitment to qualifying neurodegenerative proteinopathy transmission risks. This is especially so for 
those involving direct or facilitated access to a recipient’s brain or connected visual or nervous system such as for the treat-
ment of stroke, retinal and adult onset neurodegenerative diseases, treatments for which have already commenced. In this 
review, we assess the prospective global dissemination of advanced cell therapies founded on transplantation or exposure to 
allogeneic human cells, recap lessons learned from the historical precedents of CJD transmission and review recent advances 
and current limits in understanding of prion and other neurodegenerative disease prion-like susceptibility and transmission. 
From these we propose grounds for a reassessment of the risks of emergent advanced cell therapies to transmit neuropro-
teinopathies and suggestions to ACT developers and regulators for risk mitigation and extension of criteria for deferrals.
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Introduction
Over the past 20 years, scientific and medical research 
communities have made significant preclinical and clini-
cal progress in the development of new “advanced cell 
therapy “ (ACT) paradigms aspiring to replace, reconsti-
tute, or regenerate diseased or injured tissues, or modulate 
host-immune responses. Contrary to canonical allogeneic 
or autologous transplantation of primary or minimally 
processed tissues such as bone marrow and corneas or 
pituitary extracts as a source of growth hormone, these 
new paradigms have entailed more extensive processing 
of renewable cell sources. This has augmented scope for 
dissemination and thus potential risk of harm to recipients 
and the general population. The provenance of cell source 
material for these encompasses the spectrum of cell devel-
opmental ontogeny from early pre-implantation embryos, 
to fetal, neonatal, and extra-embryonic and adult organ-
specific tissues (i.e., pancreas, bone, fat, blood). Each 
places different constraints and requirements on the design 
and attributes of the intended ACT. These include the pro-
spective quantity, purity, proliferative capacity, lineage 
potency, and cellularity of source material and derivative 
therapeutic products; the necessity for co-administration 
with bio-compatible materials or augmentation of function 
by genetic manipulation; the extent to which mechanism of 
action is understood or defined; and the methods, reagents 
and assays used in production or quality control.
Concern for ACT biosafety has centered on qualifying 
the risk of adverse events arising from (1) uncontrolled or 
unexpected cell growth, behavior or neoplastic transforma-
tion, normally qualified through transplantation into ani-
mal models; and (2) adventitious pathogen transmission. 
The greatest concern for the latter is normally diseases 
for which there are no validated tests available to iden-
tify pathogen presence in the absence of visible symp-
toms of disease, or technology to remove infectivity if 
detected. Prion diseases of human or animal origin such as 
genetic, iatrogenic, sporadic or variant Creutzfeldt–Jacobs 
disease (g/i/s/vCJD), bovine spongiform encephalopathy 
(BSE), ovine scrapie and chronic wasting disease (CWD) 
in deer, which result in long incubating, invariably fatal 
and untreatable neurodegenerative prionopathies, have 
epitomized concern for such pathogens. Safeguards against 
these have been addressed on the basis of risk-based donor 
deferral founded on medical history and geographical 
likelihood of exposure. Unfortunately, this approach is 
increasingly challenged by the expanding recognition and 
global prevalence of prion diseases of one form or another 
and the increasing mobility of populations. In principle the 
efficacy of risk-based deferrals is determined by accuracy 
and sufficiency of information on which donor selection 
criteria is based. Rising awareness and improved under-
standing of prion susceptibility and propagation in ex vivo 
cultivated stem and derivative cells, and latterly evidence 
of prion-like transmission observed with other neurode-
generative disease-associated proteinopathies, now sub-
stantiate a reassessment of the risks that emergent ACT 
pose to transmit neuroproteinopathies to both recipients 
and the general population through secondary transmis-
sion. The latter is facilitated by the ageing and longer liv-
ing demographic which recipients represent. In this review, 
we begin by summarising the current state of allogeneic 
ACT market authorisations and estimating their global dis-
semination to date via clinical trial evaluations. For the 
latter we assess prospective patient participation in trials 
of therapeutic products derived from distinctive sources 
differing in source material growth, lineage potency and 
properties impacting on the design of their use and target 
indication. We then recap the historical precedents of CJD 
transmission and review recent advances in understanding 
of prion and other neurodegenerative disease prion-like 
susceptibility and transmission. Collectively, we propose 
these substantiate grounds for renewed assessment of 
risks of transmitting neurodegenerative disease causing 
proteinopathies (i.e., neuroproteinopathies). We suggest 
measures to mitigate such risks through research, product 
testing and extension of criteria for deferrals.
Current allogeneic ACT 
In principle ACT founded on a strategy of one allogeneic 
cell source for many recipients carries a greater risk for 
adventitious pathogen transmission to recipients and sec-
ondary infection to the general population, than one to one 
or autologous transplants. The extent of this may vary in 
accordance with: (1) how greatly cell source material can 
be renewed and expanded for dissemination; (2) the nature 
of the contaminant and the point in the process at which it 
occurs. The risk of transmitting a neuroproteinopathy will 
be greater where products are transplanted directly into the 
brain or central nervous system (CNS) or may have facili-
tated access to these by virtue of the site of their transplan-
tation (e.g., innervated proximal organs such as the eye) 
vs transplantation to a peripheral organ. However, injury 
or inflammation compromising the blood–brain barrier at 
the time of a transplant or subsequently could in principle 
elevate the risk of transmission. Further, risks of secondary 
transmission to the general population, such as via recipient 
donated blood would either be equal or greater following 
a peripheral transplant owing to facilitated exposure to the 
recipient’s circulatory system depending first on the trans-
mission potential of the proteinopathy and infected tissue. 
The likelihood of transmission to the general population 
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would of course also depend on the eligibility of the recipi-
ent to make a tissue donation post-treatment, whether owing 
to health or precautionary deferral.
Allogeneic ACTs currently under evaluation in clini-
cal studies can be conceptually distinguished on the basis 
of cell growth and lineage potency, in order of greatest 
to least: human embryo or induced pluripotent stem cells 
(hESC/hiPSC), multipotent mesenchymal stromal/stem cells 
(hMSC) or lineage committed progenitors and differentiated 
lineage or immortalized cell lines [11, 56, 66, 80, 82]. The 
latter includes diverse allogeneic cancer cell immunothera-
pies and vaccines such as major Multi-Histocompatibility 
Complex antigen matched natural killer or cytolytic T-cells, 
or inactivated tumor cell vaccines [71]. To date the only 
allogeneic cell therapy to be granted regulatory authority 
marketing authorization anywhere in the world is an hMSC 
treatment for graft versus host disease in New Zealand, 
Canada and Japan [28].
To estimate the current relative preponderance of clini-
cal evaluations of conceptually distinct ACT globally we 
interrogated the international clinical trials registry [13] for 
allogeneic embryonic, mesenchymal stem cell, or cancer cell 
vaccine based clinical interventions at phase 1–4 which are 
recruiting or completed. The outcome of this assessment is 
summarized in Fig. 1, with links to outcomes of searches 
in Table S1. Table 1 provides a non-exhaustive exemplar of 
the spectrum of allogeneic ACT in preclinical development 
and clinical evaluation. For allogeneic mesenchymal stem 
cell-based therapies, there are currently 87 trials with an 
estimated proposed participation of 4088 patients around 
the world, the greatest in North America (predominantly 
USA), Europe, and East Asia (predominantly China). These 
concern treatment of acute tissue injury, chronic degenera-
tive disorders and inflammatory disease based on bone mar-
row, adipose and extraembryonic tissue sourced cells. The 
prevalence of hESC and allogeneic cancer cell vaccines is an 
order of magnitude less. The latter, consisting of 11 studies 
and proposed cumulative participation of 356 patients, are 
predominantly in the USA. For hESC 15 trials proposing 
a total participation of 236 patients have a global distribu-
tion akin to hMSC. While trials for an hESC treatment of 
spinal cord injury and diabetes, and hiPSC based therapies 
for macular degeneration, have been initiated (reviewed in 
[83]), those hESC based trials which are currently recruiting 
or completed largely target retinal disease (11 of 15), with 
two treating neurodegenerative conditions (Parkinson’s and 
amyotrophic lateral sclerosis) and one ischemic heart dis-
ease. The choice of the eye and retinal degenerative disease 
early during ACT therapeutic validation is logical given the 
seriousness of disease, the physical accessibility of this part 
of the CNS, and the ease with which treatment efficacy can 
be measured. It is not, however, without a potentially greater 
risk of facilitating prion or prion-like pathogens to the brain. 
Iatrogenic CJD: a cautionary tale
The transmissibility of CJD presents a series of public 
health risks, including the risk of secondary transmission 
through medical or surgical intervention resulting in iatro-
genic CJD (iCJD). Historically routes of transmission have 
included corneal transplantation and neurosurgical instru-
ments, but the largest numbers of cases of iCJD worldwide 
have been through the use of cadaveric pituitary-derived 
hormones and human growth hormone-associated CJD 
(hGH-iCJD) in France, the UK and the USA and dura mater 
grafting (largely, but not exclusively in Japan) (reviewed by 
Ref. [8] and summarized in Table 2). Despite the practice 
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Fig. 1  Snapshot of current global clinical evaluation of human allo-
geneic embryonic, and mesenchymal stem cell and cell vaccine 
therapies. Inquiry of the international clinical trials registry [13] 
for recruiting or completed phase 1–4 trials for terms: “Embryo 
Stem Cells”, “Allogeneic Mesenchymal” or “Allogeneic Cell Line” 
returned 15, 87 and 11 trials verified to match the search terms, and 
an estimated participation of 236, 4088 and 356 patients, respectively. 
Results are depicted as study and participant percentages per world-
wide region, with regional definitions defined by clinical.trials.gov 
mapping algorithm. The specific countries in which trials are/have 
been conducted are as noted in parenthesis as follows: North Amer-
ica (USA and Canada); Central America (Panama); South America 
(Brazil, Argentina); Europe (Belgium, Denmark, France, Ireland, 
Italy, Netherlands, Spain, Sweden, United Kingdom); Middle East 
(Islamic Republic of Iran, Jordan, Israel); North Asia (Russian Fed-
eration, Ukraine, Kazakhstan); South Asia (India, Pakistan); East 
Asia (China, Republic of Korea, Taiwan); Southeast Asia (Malaysia, 
Vietnam); Pacifica (Australia). Further details of studies provided in 
Table S1
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of extracting growth hormone from cadaveric pituitaries 
having ended in the UK in 1985, cases of hGH-iCJD still 
occur, indicative of the 40 years or more incubation periods 
possible in these diseases and the disastrous long-term con-
sequences of inadvertent CJD transmission [72]. To this can 
be added the finding that vCJD (the human form of BSE in 
cattle) infectivity can be transmitted person-to-person via 
red cell transfusion (recent update from Ref. [86]) and factor 
VIII treatment [65].
Although CJD is very rare, the consequences of its trans-
missibility are very serious for patients and medical practi-
tioners. CJD is uniformly fatal with long incubation periods 
and no currently effective prophylaxis or therapy. This places 
potentially exposed individuals, such as recipients of vCJD 
implicated batches of blood products as being at risk for 
public health purposes of onward prion transmission. The 
reputational damage caused to the transfusion services by 
inadvertent HIV, hepatitis and CJD transmission to patient 
groups such as hemophiliacs by blood and blood products 
(e.g., [14]) should, we argue give pause for thought, and dic-
tate a need for reassessment of risks and mitigation strategies 
when considering new therapeutic modalities such as ACT. 
Compared to epidemics caused by conventional agents, it 
is worth reiterating that those involving prions appear to 
occur in slow motion, with the causes and full recogni-
tion of consequences sometimes separated by decades. It, 
therefore, seems prudent to consider the possibility of prion 
transmission by novel therapeutic modalities, including 
ACT, in advance, especially when the therapy is targeted to 
the brain and eye.
In experimental rodent prion disease models, prions 
delivered to brain spread to the eye, and those administered 
intraocularly spread along the retinotectal pathway to the 
brain ([25], reviewed by Ref. [36]). The involvement of the 
retina in forms of CJD that originate in the brain [37] and the 
few documented instances of corneal transplantation-asso-
ciated iatrogenic CJD [84] argue that similar processes per-
tain in human prion diseases. It is also now widely accepted 
that Alzheimer’s disease pathology, notably Aβ deposi-
tion, occurs in the retina in Alzheimer’s disease and animal 
models thereof (reviewed by Ref. [35]) and that this affords 
opportunities for non-invasive diagnostic and monitoring for 
Alzheimer’s disease in this accessible part of the central 
nervous system [45]. Further, formal similarities between 
Aβ seeding and prion propagation are becoming increas-
ingly accepted (see below) and these similarities include a 
primary role in disease pathogenesis and disease spread via 
neuroanatomical pathways (for example [69]). Thus, a for-
mal possibility exists that ongoing efforts to treat non-life-
threatening conditions such as blindness arising from retinal 
diseases by ACT risk facilitation of inadvertent transmission 
of fatal neurodegenerative conditions such as CJD or other 
neuroproteinopathies.
Fig. 2  Prion infection of human embryonic and induced pluripotent 
stem cells and their astrocyte derivatives. Schematic representation of 
design and outcome of author-led studies reflecting limited published 
knowledge on the susceptibility to and replication of infectious prions 
in pluripotent and derivative cells, namely [47, 48]
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Risk of prion‑disease transmission by ACT 
In principle, prion or prion-like contamination of ACT 
could arise by mechanisms mirroring aspects of the known 
etiologies of CJD itself: acquired, sporadic or genetic. 
First, it is possible that the contamination could derive 
from the donation itself. This could be in the form of 
misfolded protein that remains or propagates along with 
the cells themselves and is subsequently transmitted to 
recipients of that particular ACT product. Alternatively, 
the donated material may harbour an unrecognized muta-
tion that predisposes the encoded gene product to misfold, 
propagate or be maintained, thus contaminating the ACT 
product. Second, the cells derived and expanded from the 
donation may at some point become exposed to exogenous 
human or animal culture additives that themselves contain 
prion infectivity, and which replicates or is maintained in 
the cultured cells and transmitted to the recipients of that 
particular ACT product. Third, a spontaneous event may 
occur during the derivation and expansion of the cells, 
either at the genomic level predisposing the gene product 
to misfolding or at the epigenetic level by spontaneous pro-
tein misfolding that results in a contaminated ACT prod-
uct. These spontaneous events would be ex vivo analogues 
of the events that are thought to cause genetic and sporadic 
CJD, respectively. Last, as with all medical procedures, 
infectivity could potentially be introduced via contami-
nated instruments during the course of cell transplantation, 
a possibility that is analogous to the limited number of 
iatrogenic CJD cases associated with contaminated surgi-
cal instruments. In each of the scenarios described above 
the subsequent transmission to ACT recipients would be 
classified as iatrogenic, but the origins (and nature of 
the infectivity) would have either a sporadic, genetic or 
acquired etiology. Each of these formal possibilities mer-
its further comment here and we suggest further research 
in order to quantify and minimize the risk of inadvertent 
transmission of neuroproteinopathies by ACT.
Recently, the public perception of the risks associ-
ated with CJD has been largely driven by the outbreak 
of BSE [40] and resultant vCJD, which occurred in the 
UK, and to a lesser extent other European countries [61]. 
In vCJD, high levels of prion infectivity are more widely 
distributed throughout the body than in gCJD and sCJD, 
where it is largely confined to the CNS, and this has been 
taken to indicate a greater risk of iatrogenic transmission 
from vCJD as compared to gCJD or sCJD. The absence of 
evidence of vertical transmission from pregnant mothers 
with clinical vCJD [60] suggests a degree of protection of 
the embryo and by inference of derivative hESC. Donor 
exclusion can reasonably be expected to prevent hESC or 
other donor-derived cell lines from being established from 
individuals with or with known family histories of demen-
tia, but it is worth noting that a proportion of cases of 
gCJD lack a family history and at least some of these are 
thought to result from de novo mutation of PRNP. Despite 
the more restricted tissue distribution of infectivity in 
sCJD and gCJD, recent reports indicate that fibroblast, 
fibroblast-derived hiPSC lines and neuronal derivatives 
taken from patients with sCJD and gCJD show signs of 
prion infection [64, 90]. These findings could be inter-
preted as challenging the perceived idea that prion risks 
for ACT could be obviated entirely by avoiding cells of 
UK (and European) origin and concentrating on hiPSC 
instead of hESC. Irrespective of geographical origin, CJD 
is exceedingly rare (1–2 cases per million of population 
per annum) and it would seem statistically unlikely, even 
in the UK where BSE infection has been estimated to be 
as high as 1:2000 of the general population [29], that an 
ACT would be based on cells derived from an individual 
with clinical or asymptomatic vCJD.
The possibility that exogenous prion contamination 
could occur during human cell processing (i.e., deriva-
tion, expansion, differentiation, purification, packaging for 
delivery outside of the body) also warrants consideration. 
A priori, culture additives of human or bovine origin or 
other reagents exposed to reagents of human or bovine ori-
gin in their preparation would seem to present the highest 
potential risks. All animal reservoirs of prion infectivity 
should be considered including those whose risk of trans-
mission to humans remains relatively unexplored such as 
dromedary camels and deer [3, 87]. As regards the latter, 
CWD in deer originating in North America constitutes a 
rapidly spreading epidemic with the potential to spread to 
humans arising from the consumption of wild game. In 
recent years CWD has arrived in continental Europe [6].
We have previously shown that hESC take up and then 
rapidly clear abnormal prion protein in BSE, vCJD and 
sCJD brain homogenates experimentally inoculated into 
the culture medium (Fig. 2, [48]). Clearance is reassuring 
from a safety point of view, nevertheless we noted three 
major caveats at the time of this work: first, these were 
proliferating hESC, which might dilute out slowly repli-
cation prions. Second, the methods used to detect prions 
were of relatively low analytical sensitivity. Third, these 
were stem cells and not the derivative therapeutic products 
to be transplanted in emerging ACT. More recently, we 
have shown that astrocytes differentiated in vitro by an 
established method [77] from human-induced pluripotent 
stem cells (hiPSC) from normal donors are susceptible to 
infection with human prions from sCJD and vCJD brain in 
a genotype-dependent manner and that the infection is not 
transient and can be passed from one astrocyte culture to 
another (Fig. 2, [47]). This raises the possibility that overt 
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prion replication may be differentiation dependent and that 
low-level prion contamination may only become evident 
when appropriate cell differentiation occurs on therapeutic 
application.
CJD associated with de novo PRNP mutations does occur 
in vivo in human populations, albeit at a very low incidence. 
However, at this time there is little evidence on which to 
base an evaluation of risk of spontaneous development of 
prion or prion-like infectivity ex vivo in the course of ACT 
cell processing, except that it is reasonable to assume that 
the likelihood of acquiring a pathogenic mutation in PRNP 
will increase as a factor of time in culture and the number of 
rounds of cell division prior to therapeutic use. During cell 
culture, perturbation of endoplasmic reticulum (ER) home-
ostasis can facilitate prion replication [39] and chronic or 
acute ER stress is a de facto risk of extensive cell processing. 
Thus, ACTs founded on extensively processed cell resources 
are more likely to experience sub-optimal culture conditions 
or handling inducing ER stress. They would thus theoreti-
cally carry a greater risk of spontaneous protein misfolding 
and the potential to replicate otherwise undetectable prion 
contaminants than minimally processed cells.
There is no obvious reason to presume that the physical 
introduction of ACT products to patients bears greater 
risks of infection through the use of contaminated sur-
gical instruments than other comparable surgical inter-
ventions. Nevertheless, it is important to recognize that 
neurosurgery, ocular surgery in the form of corneal trans-
plantation, transfusion and intramuscular inoculation are 
all recognized routes of iCJD transmission (Table 2) and 
careful consideration should be given to the challenging 
physical properties of prions and prion-like infectivity 
when selecting appropriate decontamination regimes [5, 
22, 81].
Fig. 3  Currently known or suspected routes of human-to-human 
neurodegenerative disease or associated protein pathology transmis-
sion occurring as a consequence of medical treatment. Iatrogenic 
Creutzfeldt–Jakob disease and its associated  PrPSc deposition has 
been shown to occur following interventions in the brain and eye 
and via peripheral exposure in recipients of human growth hormone. 
Variant Creutzfeldt–Jakob disease has also been transmitted through 
blood transfusion. Immunostaining for disease associated prion pro-
tein  (PrPSc, brown) in the cerebellum of a recipient of human growth 
hormone is shown. Recently, amyloid beta (Aβ) neuropathology has 
been shown to occur in several distinct iatrogenic Creutzfeldt–Jakob 
disease cohorts associated with both central and peripheral exposure 
to prion infectivity. The presence of Aβ neuropathology in human 
growth hormone recipients who did not develop Creutzfeldt–Jakob 
disease indicates that Aβ neuropathology is independently transmis-
sible. Aβ deposition (brown) in the cerebral cortex and cerebral blood 
vessels of one such patient is shown. Acquired phospho-tau (p-tau), 
α-synuclein (α-syn) or TDP-43 neuropathology have yet to be dem-
onstrated
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Prion‑like mechanisms and other protein 
misfolding disorders
The hypothesis that CJD and other transmissible spongiform 
encephalopathies result from self-propagating conforma-
tional variants of the prion protein yielding a transmissible 
amyloidosis (the prion hypothesis) has in the past decade 
gone through a dramatic expansion. This owes to obser-
vations of prion-like behaviors of other proteins, such as 
beta amyloid (Aβ), tau, α-synuclein and TDP-43 that are 
proposed to underlie neurodegenerative diseases as diverse 
as Alzheimer’s disease, Parkinson’s disease, multiple sys-
tems atrophy, frontotemporal dementia and motor neuron 
disease, respectively. The case for reframing these diverse 
neurodegenerative disorders explicitly as prion diseases has 
been made [67, 68]. The original observations on which 
this assertion is based derive from cell culture and trans-
genic animal studies showing that aspects of the molecu-
lar pathology that characterize each disease and its spread 
between cells, around the brain and even between individual 
animals share fundamental similarities with those already 
defined in prion diseases. Intracerebral inoculation of Aβ 
containing brain extracts into amyloid precursor protein 
(APP) transgenic mice was first shown to be sufficient to 
result in an Aβ amyloidosis in the recipient animals [55]. 
The analogy with experimental prion disease transmission 
was further strengthened by the observations that cerebral 
Aβ amyloidosis could result from peripheral (in addition to 
central) inoculation and that phenotypic differences occurred 
dependent on the source of the inoculum and genotype of 
the recipient, a situation reminiscent of prion strains [55, 
20]. Intracerebral inoculation of brain extracts from mice 
expressing disease-associated tau mutations appears suffi-
cient to transmit a spreading tauopathy in mice expressing 
wild-type tau [12]. Similarly, intracerebral inoculation of 
brain extracts from patients with multiple systems atrophy 
(MSA) in mice hemizygous for a mutant α-synuclein gene 
appears sufficient to produce a progressive neurological 
disease sharing molecular and cellular features with MSA 
[88], a finding that extended the original observation that 
intracerebral inoculation of synthetic α-synuclein fibrils can 
precipitate Parkinson’s disease-like pathology and neurode-
generation in non-transgenic mice [52]. Structural variants 
of abnormal α-synuclein and tau have also been described 
that may account for different disease phenotypes and hence 
might be interpreted as the basis of prion-like strain effects 
[7, 24]. These observations have led to a working hypothesis 
that many of the most common neurodegenerative condi-
tions are in fact neuroproteinopathies that share a common 
molecular mechanism in which different proteins (Aβ, tau, 
α-synuclein and perhaps others) function as “propagons”, 
seeding the conversion of their normal cellular counterparts 
to the abnormal disease-associated isoform and thus spread-
ing the pathological process between cells and around the 
brain. Moreover, the finding that propagons of a given pro-
tein can exist in multiple different “conformers” or “iso-
types” that “seed” or “template” with fidelity may be taken 
to be indicative of strain-like properties. The experimen-
tal data in this area are complex and subject to differing 
interpretations, but it has been critically and authoritatively 
reviewed recently at length in a cluster of articles in this 
journal [19, 50, 85].
The possibility of actual disease transmission (acquired 
Alzheimer’s disease for example) between individuals is 
more controversial and currently lacking an epidemiologi-
cal evidence base (see for example [18]); nevertheless, it 
cannot be excluded at this point in time. Strong evidence 
that Aβ protein pathology (as distinct from Alzheimer’s 
disease) is transmissible between people has recently 
appeared and again this has come from CJD research. 
The idea that pituitary-derived human growth hormone 
recipients might have been exposed to pathological pro-
teins from Alzheimer’s or Parkinson’s disease brains (in 
addition to prion protein from CJD brain) was raised by 
Irwin et al. [41], demonstrated by Jaunmuktane et al. [42] 
and confirmed and extended by us [70] and others [9, 17]. 
Similarly, an apparently acquired cerebral Aβ angiopa-
thy has been shown to be present in iatrogenic CJD cases 
linked to dura mater grafting [9, 26, 34, 46] and in a small 
number of adult individuals without CJD, but who had 
neurosurgery in childhood [43]. The recent finding of a 
fatal Aβ amyloid angiopathy in a patient four decades after 
dura grafting and with no evidence of CJD is of particular 
significance [38]. The current state of knowledge regard-
ing known transmissions of prion and prion-like patholo-
gies in humans is summarized in schematic form with 
examples in Fig. 3 and documented in detail in Table 2. 
Taken together and in combination with the precaution-
ary principle, the implications of these data include the 
proposition that ACT risk assessment should consider the 
possibility of transmission of more common proteinopa-
thies, in addition to CJD.
Prion testing of ACT products
The development of methods to screen for prions in donated 
blood has been fraught with difficulties [14]. This is in part 
because of technical challenges: the absence of nucleic acid 
component to the agent, the shared antigenicity between host 
and agent prion protein and the very low limit of detection 
required for detection in blood from asymptomatic individu-
als. Difficulties have also arisen because the most relevant 
clinical samples for test validation are not readily available 
and because any candidate blood screening assay must be 
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both high throughput and rapid to satisfy transfusion ser-
vice need. Not all of the above considerations apply to prion 
testing of ACT products, but we appear to be approaching 
a tipping point in analytical sensitivity in prion assays with 
reports that techniques such as protein misfolding cyclic 
amplification (PMCA) or real-time quaking-induced con-
version (RT-QuIC) can detect prions in blood, CSF or urine 
from vCJD or sCJD patients [4, 15, 49, 54, 58]. Moreo-
ver, such techniques may be amenable to modifications that 
allow similarly sensitive and specific detection of other neu-
rodegenerative disease-associated misfolded protein such a 
Aβ and α-synuclein [21, 73, 78]. Rather than waiting for a 
validated test to appear that is optimized for blood transfu-
sion service need, we suggest that now is the right time to 
apply existing technologies to the specific needs of develop-
ing ACT products.
Risk mitigation
Whether or not the prion or prion-like risk is readily amena-
ble to precise assessment by emerging methods, we suggest 
that even a single ACT-mediated transmission of CJD or 
prion-like neurodegenerative disease could be catastrophic 
for confidence in the emerging field of ACTs generally. It 
is tempting to suggest that CRISPR/Cas9 mediated deletion 
of PRNP from a prospective ACT product at the time of 
derivation would offer the best protection from prion dis-
ease transmission, since cellular prion protein expression 
is a precondition for prion propagation and neurotoxicity 
(reviewed by Ref. [2]). This would also serve to prevent the 
in situ spread of protein pathology from affected host cells 
to unaffected therapeutic cells as seen in grafted Parkinson’s 
disease patient brains [51] and would, therefore, ensure 
continued ACT efficacy. Unfortunately, there is increasing 
evidence that the prion protein itself performs roles in the 
maintenance and differentiation of stem cells (reviewed by 
Refs. [33, 57]), so its deletion may have unpredictable and 
undesirable effects with respect to ACTs. Instead, we suggest 
that there are a series of reasonable and practicable precau-
tionary steps to which the community of ACT developers 
and regulators supported by public and private resources 
should commence commitment to the following:
1. Careful re-evaluation of ACT cell donor medical and 
family history selection criteria and emerging scientific 
understanding to consider risk of transmitting prion and 
prion-like proteinopathies, including, but not limited to, 
risk factors associated with Alzheimer’s disease, Par-
kinson’s disease, multiple systems atrophy and fronto-
temporal dementias, in addition to Creutzfeldt–Jakob 
disease.
2. Locus-focused gene sequencing of all candidate ACT 
cell resources and derivative therapeutic products for 
mutations associated with known pathogenic prion iso-
forms and prion-like proteinopathies.
3. Continued optimization of derivation and cell expansion 
conditions that avoid as far as possible biologicals of 
human and animal origin.
4. Commitment to develop and apply high sensitivity 
detection methods such as variations of PMCA and RT-
QuIC for prion and prion-like proteinopathies for pur-
poses of Quality Control and Release of manufactured 
ACT products.
5. Integral to the previous, development of reference stand-
ards to qualify detection of prion and prion-like pro-
teinopathies in ACT products and their dissemination 
in support of international harmonization of standards 
for the testing ACTs.
6. Basic research on the extent to which cell processing 
steps critical for ACT manufacture impacts on spontane-
ous mutations or misfolding promoting prion or prion-
like replication and infectability.
Conclusion
In summation, the available evidence substantiates the per-
spective that the risk of transmitting prion or prion-like 
proteinopathies with modern day ACT for neurological or 
other diseases is still likely to be remote. However, histori-
cal precedent and developments in the field in recent years 
does justify reassessment of precautionary measures, as out-
lined. Such effort would be consistent with the long-standing 
commitment of ACT developers, regulators and public and 
private investors to assure the future safety and efficacy of 
emerging therapeutic interventions for debilitating diseases 
yet to be effectively treated or cured by other approaches.
Search strategy and selection criteria
References used herein were identified by searches of Pub-
Med on the 15th of June 2018 or previously known to the 
authors. The search terms “Cell Therapy”, “Prion”, “Prion-
like”, “Prionopathy” and “Proteinopathy” were used. Cell 
therapies currently under clinical evaluation (Phase I–IV) 
were identified on the same date by searching the US inter-
national registry of clinical trials [13]; The final reference 
list was generated on the basis of relevance to the topics 
covered in this Review.
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